Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 1 , Pages 31-35, March 2005

Impact of Second-Trimester Maternal Serum Screening on Prenatal Diagnosis of Down Syndrome and the use of Amniocentesis in the Taiwanese Population

  • Chih-Ping Chen

      Affiliations

    • Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taichung, Taiwan
    • Department of Medical Research, Mackay Memorial Hospital, Taipei, Taichung, Taiwan
    • Department of Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei, Taichung, Taiwan
    • College of Chinese Medicine, China Medical University, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr. Chih-Ping Chen, Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan
    • ,
  • Chen-Ju Lin

      Affiliations

    • Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taichung, Taiwan
    • ,
  • Wayseen Wang

      Affiliations

    • Department of Medical Research, Mackay Memorial Hospital, Taipei, Taichung, Taiwan
    • ,
  • the Taiwan Amniocentesis Collaborative Study Group

Received 28 January 2005; received in revised form 2 February 2005; accepted 15 February 2005.

Article Outline

Summary 

Objective

To investigate the impact of second-trimester maternal serum screening on prenatal diagnosis of Down syndrome and the use of amniocentesis in the Taiwanese population.

Materials and Methods

From 1990 to 2000, 166,419 amniocenteses were analyzed cytogenetically in the Taiwanese population. Among these, 58.85% were for advanced maternal age, 4.5% for abnormal ultrasound findings, 26.17% for abnormal maternal serum screening results, 1.82% for a previous child with congenital anomaly, 1.02% for a family history of chromosome aberrations, and 7.63% for other purposes. Chromosome aberrations were detected in 4,217 cases (2.53%), of which 1,277 (30.28%) were Down syndrome. Of the Down syndrome cases, 65.86% were detected by amniocentesis for advanced maternal age, 5.95% for abnormal ultrasound findings, 21.14% for abnormal maternal serum screening results, 1.25% for a previous child with congenital anomaly, 1.18% for a family history of chromosome aberrations, and 4.62% for other purposes.

Results

There was a prominent increase in the number of women undergoing amniocentesis in the Taiwanese population between 1990 and 2000. There was an 8.9-fold increase in the number undergoing amniocentesis for advanced maternal age, a 6.3-fold increase in that for abnormal ultrasound findings, a 46.2-fold increase in that for abnormal maternal serum screening results, a 2.9-fold increase in that for a previous child with congenital anomaly, a 5.6-fold increase in that for a family history of chromosome aberrations, and a 4.4- fold increase in that for other purposes. There was also a 35.7-fold increase in the number of prenatally detected Down syndrome cases, from seven in 1990 to 250 in 2000. The highest rates of Down syndrome were found in cases with abnormal ultrasound findings (1/99 tests). Down syndrome was 0.72-fold as common in amniocenteses performed because of positive serum screening results (1/161 tests) compared with the rate seen in the advanced maternal age group (1/116 tests). The detection rates increased from 1/449 tests in 1990, through 1/198 tests, 1/203 tests, 1/158 tests, 1/215 tests, 1/229 tests, 1/169 tests, 1/143 tests, 1/90 tests, 1/92 tests, to 1/123 tests in 2000.

Conclusion

Both the number of women undergoing amniocentesis and the number of detected cases of Down syndrome increased during these years. Amniocentesis in this population no longer led to a significant improvement in the detection rate of Down syndrome. In view of the effective use of amniocentesis as a diagnostic procedure for Down syndrome, efforts should be made to use more efficient prenatal screening programs and to reduce the number of unnecessary amniocenteses.

Key Words:  amniocentesis , Down syndrome , maternal serum screening

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Benn PA , Egan JFX , Fang M , Smith-Bindman R . Changes in the utilization of prenatal diagnosis . Obstet Gynecol . 2004;103:1255–1260
  2. Cheffins T , Chan A , Haan EA , et al.   The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia . Br J Obstet Gynecol . 2000;107:1453–1459
  3. Khoshnood B , De Vigan C , Vodovar V , Goujard J , Goffinet F . A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981–2000 . Br J Obstet Gynecol . 2004;111:485–490
  4. Shohat M , Frimer H , Shohat-Levy V , et al.   Prenatal diagnosis of Down syndrome: ten year experience in the Israeli population . Am J Med Genet . 2003;122A:215–222
  5. Smith-Bindman R , Chu P , Bacchetti P , Waters JJ , Mutton D , Alberman E . Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes . Am J Obstet Gynecol . 2003;189:980–985
  6. Verloes A , Gillerot Y , Van Maldergem L , et al.   Major decrease in the incidence of trisomy 21 at birth in south Belgium: mass impact of triplet test? . Eur J Hum Genet . 2001;9:1–4

PII: S1028-4559(09)60103-0

doi:10.1016/S1028-4559(09)60103-0

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 1 , Pages 31-35, March 2005

Article Tools